

Thomas Aparicio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1837410/publications.pdf>

Version: 2024-02-01

119
papers

3,069
citations

186265

28
h-index

189892

50
g-index

119
all docs

119
docs citations

119
times ranked

4632
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.9	3
2	Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. <i>Gut</i> , 2023, 72, 699-709.	12.1	8
3	Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment for metastatic melanoma: a case report. <i>Annals of Palliative Medicine</i> , 2022, 11, 837-842.	1.2	5
4	Effect of lockdown on digestive system cancer care amongst older patients during the first wave of COVID-19: The CADIGCOVAGE multicentre cohort study. <i>Digestive and Liver Disease</i> , 2022, 54, 10-18.	0.9	7
5	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. <i>British Journal of Cancer</i> , 2022, 126, 1264-1270.	6.4	15
6	Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database. <i>Cancers</i> , 2022, 14, 1105.	3.7	2
7	The Pre-Operative GRADE Score Is Associated with 5-Year Survival among Older Patients with Cancer Undergoing Surgery. <i>Cancers</i> , 2022, 14, 117.	3.7	2
8	Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4427.	4.1	6
9	Epidemiology, Risk Factors and Diagnosis of Small Bowel Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2268.	3.7	13
10	Safety of FOLFIRI + Durvalumab +/â~ Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. <i>Biomedicines</i> , 2022, 10, 1211.	3.2	3
11	A decision curve analysis of the clinical usefulness of a two-step frailty assessment strategy in older patients with prostate, breast, colorectal, or lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12011-12011.	1.6	1
12	The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4036-4036.	1.6	2
13	Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3555-3555.	1.6	0
14	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	6.3	5
15	Panel gene profiling of small bowel adenocarcinoma: Results from the <scp>NADEGE</scp> prospective cohort. <i>International Journal of Cancer</i> , 2021, 148, 1731-1742.	5.1	21
16	MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 193.	3.7	7
17	Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer. <i>BMC Medical Research Methodology</i> , 2021, 21, 14.	3.1	3
18	Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , 2021, 10, 1940674.	4.6	11

#	ARTICLE	IF	CITATIONS
19	Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). <i>Digestive and Liver Disease</i> , 2021, 53, 306-308.	0.9	8
20	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.9	10
21	The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcS@-Crizotinib Program. <i>Targeted Oncology</i> , 2021, 16, 381-388.	3.6	17
22	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202.	7.7	14
23	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , 2021, 150, 232-239.	2.8	11
24	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3242-3250.	1.6	35
25	Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in F@ction Francophone de Canc@rologie Digestive (FFCD) trials. <i>European Journal of Cancer</i> , 2021, 153, 40-50.	2.8	2
26	Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 922-932.	8.1	21
27	Tumors: Colorectal. , 2021, , 5222-5234.		0
28	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. <i>Gut</i> , 2020, 69, 531-539.	12.1	97
29	Comparison of Mobility Indices for Predicting Early Death in Older Patients With Cancer: The Physical Frailty in Elderly Cancer Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 189-196.	3.6	29
30	Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD@NADEGE cohort study of 347 patients. <i>International Journal of Cancer</i> , 2020, 147, 967-977.	5.1	57
31	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020, 52, 1143-1147.	0.9	2
32	Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study. <i>EBioMedicine</i> , 2020, 60, 102979.	6.1	2
33	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CAC@VID-19). <i>European Journal of Cancer</i> , 2020, 141, 62-81.	2.8	122
34	Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer. <i>European Journal of Cancer</i> , 2020, 141, 143-151.	2.8	10
35	Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 @ REGOLD. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1255-1262.	1.0	12
36	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , 2020, 19, 285-290.	2.3	5

#	ARTICLE	IF	CITATIONS
37	Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2020, 12, 1429.	3.7	7
38	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	6.4	4
39	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020, 147, 285-296.	5.1	56
40	Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). <i>Digestive and Liver Disease</i> , 2020, 52, 493-505.	0.9	17
41	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0230914.	2.5	16
42	COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2020, 52, 597-603.	0.9	37
43	Development, validation and clinical impact of a prediction model for 6-month mortality in older cancer patients: the GRADE. <i>Aging</i> , 2020, 12, 4230-4246.	3.1	13
44	Tumors: Colorectal. , 2020, , 1-13.		0
45	Colorectal Cancer in Older Adults: Systemic Treatments. , 2020, , 701-711.		0
46	Title is missing!. , 2020, 15, e0230914.		0
47	Title is missing!. , 2020, 15, e0230914.		0
48	Title is missing!. , 2020, 15, e0230914.		0
49	Title is missing!. , 2020, 15, e0230914.		0
50	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	6.1	24
51	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1153-1161.	2.5	14
52	Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. <i>European Journal of Cancer</i> , 2019, 123, 92-100.	2.8	3
53	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	2.8	29
54	Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). <i>Radiotherapy and Oncology</i> , 2019, 140, 84-89.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study. EBioMedicine, 2019, 41, 276-285.	6.1	19
56	Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. , 2019, 7, 74.		151
57	Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. European Journal of Surgical Oncology, 2019, 45, 331-335.	1.0	24
58	Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) study. Clinical Nutrition, 2019, 38, 2806-2812.	5.0	18
59	Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).. Journal of Clinical Oncology, 2019, 37, 3570-3570.	1.6	2
60	Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. Oncologist, 2019, 24, e1351-e1359.	3.7	42
61	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. Journal of Clinical Oncology, 2019, 37, 3550-3550.	1.6	1
62	BIONADEGE: Genomic profiling of small bowel adenocarcinoma from the NADEGE prospective cohort.. Journal of Clinical Oncology, 2019, 37, 4140-4140.	1.6	0
63	Implementation of complex perioperative intervention in older patients with cancer (IMPROVED) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	0
64	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). Digestive and Liver Disease, 2018, 50, 408-410.	0.9	14
65	Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. International Journal of Colorectal Disease, 2018, 33, 1125-1130.	2.2	16
66	Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study. European Journal of Surgical Oncology, 2018, 44, 799-804.	1.0	3
67	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Digestive and Liver Disease, 2018, 50, 305-307.	0.9	13
68	Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1875626.	3.2	12
69	Chronological Age and Risk of Chemotherapy Nonfeasibility.. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 73-80.	1.3	15
70	Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digestive and Liver Disease, 2018, 50, 15-19.	0.9	60
71	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With <i>RAS</i> and <i>BRAF</i> Mutational Status. JAMA Oncology, 2018, 4, e173695.	7.1	55
72	Reply to M. Mo et al. Journal of Clinical Oncology, 2018, 36, 2452-2453.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	1.6	70
74	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. <i>European Journal of Cancer</i> , 2018, 98, 1-9.	2.8	30
75	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 4745-4753.	7.0	23
76	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018, 119, 424-428.	6.4	22
77	Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcS�� Program.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2504-2504.	1.6	8
78	FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4000-4000.	1.6	43
79	Colorectal Cancer in Older Adults: Systemic Treatments. , 2018, , 1-11.		0
80	The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcS��-crizotinib program.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4054-4054.	1.6	1
81	Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3568-3568.	1.6	0
82	Genomic Profiling of Small-Bowel Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 1546.	7.1	154
83	Preferences about information and decision-making among older patients with and without cancer. <i>Age and Ageing</i> , 2017, 46, 665-671.	1.6	24
84	Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database. <i>Targeted Oncology</i> , 2017, 12, 805-814.	3.6	16
85	Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 74, 98-108.	2.8	41
86	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3515-3515.	1.6	3
87	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3520-3520.	1.6	2
88	Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3601-3601.	1.6	12
89	Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 350-350.	1.6	2
90	Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients: the prospective PF-EC cohort study. <i>Oncotarget</i> , 2017, 8, 50393-50402.	1.8	21

#	ARTICLE	IF	CITATIONS
91	Classic or simplified LV5FU2 regimen: Multivariate analysis from a phase III study in metastatic colorectal cancer in elderly patients.. Journal of Clinical Oncology, 2017, 35, 3550-3550.	1.6	0
92	Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.. Journal of Clinical Oncology, 2017, 35, e15034-e15034.	1.6	0
93	PRODIGE 34 ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancerâ€”A randomized phase III trial.. Journal of Clinical Oncology, 2017, 35, TPS3628-TPS3628.	1.6	0
94	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. Digestive and Liver Disease, 2016, 48, 1498-1502.	0.9	8
95	Small Bowel Adenocarcinoma. Gastroenterology Clinics of North America, 2016, 45, 447-457.	2.2	48
96	Colorectal cancer care in elderly patients: Unsolved issues. Digestive and Liver Disease, 2016, 48, 1112-1118.	0.9	36
97	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. Journal of the National Cancer Institute, 2016, 108, djv438.	6.3	127
98	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 154-160.	1.5	33
99	PRODIGE 34 â€” FFCO 1402 â€” ADAGE. Digestive and Liver Disease, 2016, 48, 206-207.	0.9	26
100	Safety and efficacy of palliative systemic chemotherapy combined with colorectal self-expandable metallic stents in advanced colorectal cancer: A multicenter study. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 230-238.	1.5	20
101	GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. Journal of Clinical Oncology, 2016, 34, TPS4154-TPS4154.	1.6	9
102	Magnetic resonance imaging diffusion-weighted imaging for diagnosis of a gastric hepatoid adenocarcinoma. Digestive and Liver Disease, 2015, 47, 174.	0.9	5
103	FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 â€” FFCO 0802). Digestive and Liver Disease, 2015, 47, 271-272.	0.9	13
104	Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. International Journal of Colorectal Disease, 2015, 30, 1305-1310.	2.2	30
105	High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCO 0504 Study. Molecular Cancer Therapeutics, 2015, 14, 2782-2788.	4.1	9
106	PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)â€”A randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 3541-3541.	1.6	34
107	Adjuvant chemotherapy by FOLFOX for gastric hepatoid adenocarcinoma. Digestive and Liver Disease, 2014, 46, 1135-1136.	0.9	11
108	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 2014, 50, 2983-2993.	2.8	56

#	ARTICLE	IF	CITATIONS
109	High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 384-388.	1.0	21
110	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1740-1746.	2.8	79
111	Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 97-104.	0.9	245
112	Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. <i>Digestive and Liver Disease</i> , 2013, 45, 245-250.	0.9	40
113	Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 1464-1470.	1.6	192
114	Prognostic factors of recurrence of colorectal cancers with microsatellite instability after curative resection: An AGEO retrospective multicenter study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3536-3536.	1.6	1
115	Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert's disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3614-3614.	1.6	2
116	Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy. <i>Cancer</i> , 2011, 117, 1422-1428.	4.1	71
117	Nutritional Status Affects Treatment Tolerability and Survival in Metastatic Colorectal Cancer Patients: Results of an AGEO Prospective Multicenter Study. <i>Oncology</i> , 2011, 81, 395-402.	1.9	80
118	Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 249-257.	4.4	92
119	Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. <i>Gastroenterology</i> , 2004, 126, 499-510.	1.3	65